1 10 5 https://ciencia.lugoneseditorial.com.ar/files/original/dba27c25125f3c7bcda181fe2c46927b.pdf abf1c90dbbfd089f1ec6e595e6c70e76 Hyperlink A link, or reference, to another resource on the Internet. URL <a href="https://lugoneseditorial.com.ar/novedades/dermatologia/hidroxiapatita-calcio/">https://lugoneseditorial.com.ar/novedades/dermatologia/hidroxiapatita-calcio/</a> Dublin Core The Dublin Core metadata element set is common to all Omeka records, including items, files, and collections. For more information see, http://dublincore.org/documents/dces/. Title A name given to the resource Evaluation of 80 mg/ml calcium hydroxyapatite in the treatment of nasolabial folds. Analysis of durability, safety, and efficacy at 12 months Description An account of the resource Introduction: skin aging involves collagen fragmentation, which affects the extracellular matrix and accelerates deterioration. Photoaging, caused by ultraviolet radiation, motivates patients to seek corrective treatments. Calcium hydroxyapatite (CaHA) is a biocompatible filler that stimulates collagen production and provides safe and long-lasting results with a low complication rate. Correction of the nasolabial fold (NLF) is key to facial aesthetics, and CaHA has been shown to be effective in improving appearance and rejuvenating the face. Objectives: demonstrate the efficacy and safety of Cientific Permanent Facial Implant II® (CaHA 80 mg/ml) for the correction of mild to moderate NLF.1 Materials and methods: a multicenter, prospective, open-label, longitudinal clinical study included 122 patients of both sexes (35–65 years old) with mild to moderate nasolabial folds (NLF). A maximum of 1 ml of CaHA filler was applied per fold, with the possibility of reapplication after 9 months in selected cases clinical parameters of efficacy, safety, and duration of effect were assessed using validated scales at baseline and at 3, 6, 9, and 12 months. The Lemperle scale was used for the initial patient assessment, and improvements were also assessed using this scale and the Global Aesthetic Improvement Scale (GAIS) and photographs of each follow-up. Results: the study confirmed the safety and efficacy of Cientific Permanent Facial Implant II® (CaHA 80 mg/ml) for the correction of NLF, with mild adverse events such as pain, erythema, edema and ecchymosis, all transient and resolved spontaneously. At 12 months, the majority of patients maintained satisfactory results, with a high rate of improvement according to the GAIS scale. Only two patients were evaluated outside the protocol for asymmetries, and only one required correction. All participants attended the established follow-up visits, demonstrating adherence to the study and stability of the treatment. Conclusions: Cientific Permanent Facial Implant II® (CaHA 80 mg/ml) was shown to be an effective and safe treatment for the correction of mild to moderate NLF. Reapplication after 9 months optimizes the duration of the effect in certain patients Creator An entity primarily responsible for making the resource Ivanna Laura Salerno, Plastic Surgeon, Director of the Dr. Ivanna Salerno Center, City of Buenos Aires, Argentina. ORCID: <a href="https://orcid.org/0009-0004-5430-5683">https://orcid.org/0009-0004-5430-5683</a> Claudio Dachevsky, Plastic Surgeon, General Manager, Lipo Plastic Surgery Clinic, São Paulo, Brazil. ORCID: <a href="https://orcid.org/0009-0006-5400-0585">https://orcid.org/0009-0006-5400-0585</a> Source A related resource from which the described resource is derived Cientific Permanent Facial Implant II® Publisher An entity responsible for making the resource available Lugones Editorial Date A point or period of time associated with an event in the lifecycle of the resource 26/05/2025 Contributor An entity responsible for making contributions to the resource Cientific Permanent Facial Implant II® Identifier An unambiguous reference to the resource within a given context <a href="https://doi.org/10.47196/0596">https://doi.org/10.47196/0596</a> aesthetic medicine biostimulation CaHA calcium hydroxyapatite dermal fillers nasolabial folds https://ciencia.lugoneseditorial.com.ar/files/original/a99411b509f6b3485fb4c2272a46cd81.pdf 4c176201408ce815a005919d9835d6c2 Hyperlink A link, or reference, to another resource on the Internet. URL <a href="https://lugoneseditorial.com.ar/novedades/dermatologia/acido-hialuronico-nasolabiales/">https://lugoneseditorial.com.ar/novedades/dermatologia/acido-hialuronico-nasolabiales/</a> Dublin Core The Dublin Core metadata element set is common to all Omeka records, including items, files, and collections. For more information see, http://dublincore.org/documents/dces/. Title A name given to the resource Evaluation of the efficacy and safety of cross-linked hyaluronic acid 30 mg/ml for filling nasolabial folds Description An account of the resource Introduction: the nasolabial folds (NLF) are a highly mobile facial region that undergoes multifactorial changes during aging. Cientific Hyaluronic Facial Implant 30® is a 30 mg/ml cross-linked hyaluronic acid (HRA) filler developed to optimize the results of this highly dynamic facial area. Objectives: to evaluate the safety and efficacy of Cientific Hyaluronic Facial Implant 30® (CH30), composed of 30 mg/ml HRA, for the correction of moderate to severe NLF. Materials and methods: a 12-month, prospective, multicenter clinical study that included 64 male and female patients between 30 and 75 years of age with moderate to severe NLF treated in both NLFs with CH30 to balance the asymmetry until optimal correction was achieved. Efficacy assessments by evaluators included analysis of NLF severity using the Wrinkle Severity Rating Scale (WSRS) and improvement using the Global Aesthetic Improvement Scale (GAIS). Safety was recorded throughout the study based on checks at each appointment and patient reporting of adverse events. Results: no adverse events were observed during the 12-month follow-up. In 100% of cases, defect correction, duration, and satisfaction were rated by patients and physicians as “improved” to “very improved,” with a very slow decrease in effect observed at 12 months. Conclusions: the use of AHR for the treatment of NLF is one of the most effective and safe options in current aesthetic medicine. Its ability to restore volume, smooth wrinkles, and improve skin quality make it a key tool for facial rejuvenation. The durability of the results, combined with its low complication rate, makes HRA widely recommended for patients seeking a natural and longlasting aesthetic improvement, making it one of the most popular interventions in modern aesthetic medicine. Creator An entity primarily responsible for making the resource Claudio Dachevsky: Plastic Surgeon, General Manager, Lipo Plastic Surgery Clinic, São Paulo, Brazil Source A related resource from which the described resource is derived I. Russell-Goldman E, Murphy GF. The pathobiology of skin aging. New insights into an old dilemma. Am J Pathol 2020 Jul;190(7):1356-1369. doi: 10.1016/j. ajpath.2020.03.007. II. Lupo M. Hyaluronic acid fillers in facial rejuvenation. Seminars in cutaneous medicine and surgery 2006; 25:122-6. doi: 10.1016/j.sder.2006.06.011. III. Duranti F, Salti G, Bovani B, Calandra M, Rosati ML. Injectable hyaluronic acid gel for soft tissue augmentation. A clinical and histological study. Dermatol Surg 1998 Dec;24(12):1317-25. doi: 10.1111/ j.1524-4725.1998.tb00007.x. IV. Braccini F, Fanian F, García P, et al Comparative clinical study for the efficacy and safety of two different hyaluronic acid-based fillers with Tri-Hyal versus Vycross technology. A long-term prospective randomized clinical trial. J Cosmet Dermatol 2023. Feb;22(2):473-485. doi: 10.1111/jocd.15200. V. Peña F. Factores relacionados a la durabilidad del ácido hialurónico reticulado. Rev Facultad de Medicina de la Universidad de lberoamérica 2023;2;13-21. doi 10.54376/rcmui.v2i2.148. VI. Wongprasert P, Dreiss CA, Murray G. Evaluating hyaluronic acid dermal fillers. A critique of current characterization methods. Dermatol Ther 2022 Jun;35(6):e15453. doi: 10.1111/dth.15453. VII. Sánchez-Carpintero D, Ruiz-Rodríguez R. Materiales de relleno: tipos, indicaciones y complicaciones. Actas Dermosifiliogr 2010;101(5):381-393. VIII. Bukhari SNA, Roswandi NL, Waqas M, Habib H, Hussain F, et al. Hyaluronic acid, a promising skin rejuvenating biomedicine. A review of recent updates and pre-clinical and clinical investigations on cosmetic and nutricosmetic effects. Int J Biol Macromol. 2018 Dec;120(Pt B):1682-1695. doi: 10.1016/j. ijbiomac.2018.09.188. IX. Martínez-Carpio PA, Vega López PM. Materiales de relleno temporales en medicina estética: revisión de la literatura sobre la incidencia de efectos adversos y complicaciones. Medicina Estética 2019;59(2):14-19. doi: 10.48158/MedicinaEstetica.059.02 X. Cifuentes-Mimoso T, Signes-Soler F. Estudio de efectos adversos tras tratamiento con implantes cutáneos de ácido hialurónico. Universitat Autonoma de Barcelona. Disponible en: https://semcc.com/master/files/Hialuronico%20y%20efectos%20adversos%20-%20Dras.%20Cifuentes%20y%20Signes.pdf. XI. Robles M. Estudio de seguridad y eficacia del ácido hialurónico reticulado en relleno de surcos nasolabiales. doi: 10.47196/0573. XII. Bogdan-Allemann I, Baumann L. Hyaluronic acid gel (Juvéderm) preparations in the treatment of facial wrinkles and folds. Clin Interv Aging 2008;3(4):629-34. Doi: 10.2147/cia.s3118. XIII. Jordan DR. Delayed inflammatory reaction to hyaluronic acid (Restylane). Ophthalmic Plast Reconstr Surg 2005 Sep;21(5):401-2. doi: 10.1097/01.iop.0000173194.18050.b8. XIV. NASHATM. The monograpf. Disponible en: https://es.scribd.com/document/507252742/Monograph-ofNASHA. XV. Cornejo P, Alcolea JM, Trelles MA. Perspectivas en el uso de materiales de relleno inyectables para tejidos blandos, desde nuestra experiencia. 1º parte. Cir Plast Iberolatinoam 2011;37(4):393-402. doi: 10.4321/S037678922011000400013. XVI. Day D, Littler C, Swift R, Gottlieb S. The Wrinkle Severity Scale. American Journal of Clinical Dermatology 2004;5:49-52. doi: 10.2165/00128071-200405010-00007. XVII. Dibernardo G, DiBernardo B. Prediction of treatment outcomes for neck rejuvenation Utilizing a unique classification system of treatment approach using a 1440-nm side-firing laser. Aesthetic Surgery Journal 2018;38:S43-S51. doi:10.1093/asj/sjy066. Ther 2022 XVIII. Sundaram H, Shamban A, Schlessinger J, Kaufman. Janette J, Joseph, JH, Lupin M, Draelos Z, Carey W, Smith S, Eaton L. Efficacy and safety of a new resilient hyaluronic acid filler in the correction of moderateto-severe dynamic perioral rhytides. A 52-week prospective, multicenter, controlled, randomized, evaluator-blinded study. Dermatol Surg. 2022 Jan 1;48(1):87-93. doi: 10.1097/DSS.0000000000003238. XIX. Abduljabbar MH, Basendwh MA. Complications of hyaluronic acid fillers and their managements. Journal of Dermatology & Dermatologic Surgery 2016;20(2). doi: 10.1016/j.jdds.2016.01.001. XX. Instrucciones de uso del producto Cientific Hyaluronic Facial Implant 30. Disponible en: https://es.scribd.com/document/265233528/Cientific-Hyaluronic-FacialImplant-30y18. XXI. Kaufman-Janette J, Taylor SC, Cox SE, Weinkle SH, Smith S, Kinney BM. Efficacy and safety of a new resilient hyaluronic acid dermal filler, in the correction of moderate-to-severe nasolabial folds. A 64-week, prospective, multicenter, controlled, randomized, doubleblind and within-subject study. J Cosmet Dermatol 2019 Oct;18(5):1244-1253. doi: 10.1111/jocd.13100. XXII. Dayan S, Maas CS, Grimes PE, Beer K, Monheit G, Snow S, Murphy DK, Lin V. Safety and effectiveness of VYC17.5L for long-term correction of nasolabial folds. Aesthet Surg J 2020 Jun 15;40(7):767-777. doi: 10.1093/asj/sjz200. Publisher An entity responsible for making the resource available Lugones Editorial Date A point or period of time associated with an event in the lifecycle of the resource 31/03/2025 Contributor An entity responsible for making contributions to the resource Allanmar International Company S.R.L Identifier An unambiguous reference to the resource within a given context DOI: https://doi.org/10.47196/0590 Claudio Dachevsky Cross-linked hyaluronic acid Effectiveness Facial rejuvenation Hyaluromax hyaluronic acid Marcelo Robles nasolabial folds safety https://ciencia.lugoneseditorial.com.ar/files/original/fae7fc727b7cec893cd1a699fd08f204.pdf 5e9f126e925d57252fa6089324399bad Hyperlink A link, or reference, to another resource on the Internet. Local URL The URL of the local directory containing all assets of the website <a href="https://lugoneseditorial.com.ar/novedades/dermatologia/hidroxiapatita-de-calcio-surcos-nasolabiales/">https://lugoneseditorial.com.ar/novedades/dermatologia/hidroxiapatita-de-calcio-surcos-nasolabiales/</a> URL <a href="https://lugoneseditorial.com.ar/novedades/dermatologia/hidroxiapatita-de-calcio-surcos-nasolabiales/">https://lugoneseditorial.com.ar/novedades/dermatologia/hidroxiapatita-de-calcio-surcos-nasolabiales/</a> Dublin Core The Dublin Core metadata element set is common to all Omeka records, including items, files, and collections. For more information see, http://dublincore.org/documents/dces/. Title A name given to the resource Calcium hydroxyapatite in nasolabial folds Description An account of the resource Evaluation of the safety and efficacy of calcium hydroxyapatite in the treatment of nasolabial folds. Creator An entity primarily responsible for making the resource Editor: María Fernanda Cristoforetti Source A related resource from which the described resource is derived I. Vera-Ramírez V, Morales-Sánchez MA, Santa-Cruz FJ, Medina-Bojórquez A. Escalas clínicas para evaluar el envejecimiento cutáneo: una revisión de la literatura. Rev Centro Dermatol Pascua 2021;2:68-75. doi: 10.35366/101176. II. Li K, Meng F, Li YR, Tian Y, Chen H, Jia Q, Cai H, Jiang HB. Application of nonsurgical modalities in improving facial aging. Int J Dent 2022 Feb 24;2022:8332631. doi: 10.1155/2022/8332631. III. Ogden S, Griffiths TW. A review of minimally invasive cosmetic procedures. Br J Dermatol 2008;159:1036-1050. doi: 10.1111/j.1365-2133.2008 .08845.x. IV. Sánchez-Carpintero I, Candelas D, Ruiz-Rodríguez R. Dermal fillers: types, indications, and complications. Actas Dermosifilogr 2010;101(5):381-393. doi: 10.1016/j.ad.2010.01.004 V. Bass LS, Smith S, Busso M, McClaren M. Calcium hydroxylapatite (Radiesse) for treatment of nasolabial folds: long-term safety and efficacy results. Aesthet Surg J 2010 Mar;30(2):235-8. doi: 10.1177/1090820X10366549. Publisher An entity responsible for making the resource available Lugones Editorial Date A point or period of time associated with an event in the lifecycle of the resource 08/07/2024 Format The file format, physical medium, or dimensions of the resource Website Language A language of the resource Español calcium hydroxyapatite dermal fillers duration efficacy nasolabial folds safety https://ciencia.lugoneseditorial.com.ar/files/original/d917f48efc9817f0e90e9bca5ef43ffe.pdf fca41daa9e2aeeea547aff1d1c9010d9 Dublin Core The Dublin Core metadata element set is common to all Omeka records, including items, files, and collections. For more information see, http://dublincore.org/documents/dces/. Subject The topic of the resource Dermatología Title A name given to the resource Trabajos originales Publisher An entity responsible for making the resource available Sello Editorial Lugones Date A point or period of time associated with an event in the lifecycle of the resource 12/12/2023 Contributor An entity responsible for making contributions to the resource Futerman International Products Format The file format, physical medium, or dimensions of the resource Página web: https://www.lugoneseditorial.com.ar/novedades/estudio-prospectivo-evaluacion-de-la-eficacia-y-longevidad-del-acido-hialuronico-reticulado-en-relleno-de-surcos-nasolabiales/ Language A language of the resource Español Dublin Core The Dublin Core metadata element set is common to all Omeka records, including items, files, and collections. For more information see, http://dublincore.org/documents/dces/. Title A name given to the resource Safety and efficacy study of cross-linked hyaluronic acid filler in nasolabial folds Subject The topic of the resource <em>Dermatology</em> Description An account of the resource <strong>Introduction</strong>: facial aging causes cellular and anatomical changes, resulting in loss of soft tissue volume. Due to aesthetic demand, hyaluronic acid is a very good option for filling facial folds and wrinkles. <strong>Objectives</strong>: verify the effectiveness and safety of the application of cross-linked hyaluronic acid (CLHA) for filling nasolabial folds and its permanence over time. <strong>Design</strong>: observational and descriptive clinical, longitudinal and prospective, 12 months long. Materials and methods: a total of 100 patients (86 women and 14 men) with moderate to severe nasolabial folds were studied between July 2018 and December 2019. CLHA 30 mg/ml was used for facial filler (Estrianon Hyaluronic Implant 30®, Allanmar International Company S.R.L., Argentina) <strong>Results</strong>: the adverse effects subsided within 7 days in 97% of the patients and in the rest of the patients within 14 days. The initial application was up to 1 ml per groove in the most severe cases. Regarding its effectiveness as a filler, its average duration was found to be up to 8 months with the corresponding reapplications. <strong>Conclusions</strong>: Estrianon Hyaluronic Implant 30® is a safe product, its duration depends largely on the age of the patient, their habits and the condition of their skin, exceeding 8 months and up to a year. Creator An entity primarily responsible for making the resource <span>Editora: María Fernanda Cristoforetti</span> Source A related resource from which the described resource is derived I. Scardovi S, Goglian A, Gendra P, Gendra C. Clinical study of the efficacy, duration and adverse effects of hyaluronic acid implants in the oral-maxillofacial área. Odontoestomatol 2017;19(30):78-91. doi: 10.22592/ o2017n30a9. II. Trévidic P, Kaufman-Janette J, Weinkle S, Wu R, Dhillon B, Antunes S, Macé E, Maffert P. Injection guidelines for treating midface volume deficiency with hyaluronic acid fillers: The ATP Approach (Anatomy, Techniques, Products). Aesthet Surg J 2022 Aug 1;42(8):920-934. doi: 10.1093/asj/sjac007. III. Faivre J, Gallet M, Tremblais E, Trévidic P, Bourdon F. Advanced concepts in rheology for the evaluation of hyaluronic acid-based soft tissue fillers. Dermatol Surg. 2021 May 1;47(5):e159-e167. doi: 10.1097/ DSS.0000000000002916. IV. Cifuentes-Mimoso T, Signes-Soler F. Estudio de efectos adversos tras tratamiento con implantes cutáneos de ácido hialurónico. Universitat Autonoma de Barcelona. Disponible en: https://semcc.com/master/ files/Hialuronico%20y%20efectos%20adversos%20-%20 Dras.%20Cifuentes%20y%20Signes.pdf. V. Snibson GR, Greaves JL, Soper ND, Prydal JI, Wilson CG, Bron AJ. Precorneal residence times of sodium hyaluronate solutions studied by quantitative gamma scintigraphy. Eye (Lond) 1990;4 (Pt 4):594-602. doi: 10.1038/eye.1990.83. VI. Sourdille P, Santiago PY, Villain F, Yamamichi M, Tahi H, Parel JM, Ducournau Y. Reticulated hyaluronic acid implant in nonperforating trabecular surgery. J Cataract Refract Surg 1999 Mar;25(3):332-9. doi: 10.1016/s08863350(99)80080-7. VII. He Z, Han S, Zhen Z, Ding X, Liang S. The clinical use of sodium hyaluronate eyedrops as a substitute for tears. Yan Ke Xue Bao 1990 Dec;6(3-4):111-2. VIII. Petrella RJ, DiSilvestro MD, Hildebrand C. Effects of hyaluronate sodium on pain and physical functioning in osteoarthritis of the knee: a randomized, doubleblind, placebo-controlled clinical trial. Arch Intern Med 2002 Feb 11;162(3):292-8. doi: 10.1001/archinte.162.3.292. IX. Raynauld JP, Torrance GW, Band PA, Goldsmith CH, Tugwell P, Walker V, Schultz M, Bellamy N; Canadian Knee OA Study Group. A prospective, randomized, pragmatic, health outcomes trial evaluating the incorporation of hylan G-F 20 into the treatment paradigm for patients with knee osteoarthritis (Part 1 of 2): clinical results. Osteoarthritis Cartilage 2002 Jul;10(7):506-17. doi: 10.1053/joca.2002.0798. X. Tamer TM. Hyaluronan and synovial joint: function, distribution and healing. Interdiscip Toxicol 2013 Sep;6(3):111-25. doi: 10.2478/intox-2013-0019. XI. Altman RD, Moskowitz R. Intraarticular sodium hyaluronate (Hyalgan) in the treatment of patients with osteoarthritis of the knee: a randomized clinical trial. Hyalgan Study Group. J Rheumatol 1998 Nov;25(11):220312. Erratum in: J Rheumatol 1999 May;26(5):1216. XII. Bogdan-Allemann I, Baumann L. Hyaluronic acid gel (Juvéderm) preparations in the treatment of facial wrinkles and folds. Clin Interv Aging 2008;3(4):629-34. doi: 10.2147/cia.s3118. XIII. Jordan DR. Delayed inflammatory reaction to hyaluronic acid (Restylane). Ophthalmic Plast Reconstr Surg. 2005 Sep;21(5):401-2. doi: 10.1097/01.iop.0000173194.18050.b8. XIV. Ågerup B, Wik O. The MonographnashaTM. 2008. Disponible en: https://docplayer.net/20739410-Nashathe-monograph-1.html. XV. Cornejo P, Alcolea JM, Trelles MA. Perspectivas en el uso de materiales de relleno inyectables para tejidos blandos, desde nuestra experiencia. 1º parte. Cir Plást Iberolatinoam 2011;37(4):393-402. XVI. Smith SR, Jones D, Thomas JA, Murphy DK, Beddingfield FC. Duration of wrinkle correction following repeat treatment with Juvéderm hyaluronic acid fillers. Arch Dermatol Res 2010 Dec;302(10):757-62. doi: 10.1007/ s00403-010-1086-8. XVII. Monheit G, Beer K, Hardas B, Grimes PE, Weichman BM, Lin V, Murphy DK. Safety and effectiveness of the hyaluronic acid dermal filler VYC-17.5L for nasolabial folds. Results of a randomized, controlled study. Dermatol Surg 2018 May;44(5):670-678. doi: 10.1097/ DSS.0000000000001529. XVIII. Galderma. Instrucciones de uso. Disponible en: https:// www.galderma.com/us/sites/default/files/2018-11/ Restylane_IFU.pdf. XIX. Allergan. Instrucciones de uso. Disponible en https:// www.rxabbvie.com/pdf/juvederm-ultra-plus-xc_dfu.pdf. XX. Day DJ, Littler CM, Swift RW, Gottlieb S. The Wrinkle Severity Rating Scale: a validation study. Am J Clin Dermatol 2004;5(1):49-52. doi: 10.2165/00128071200405010-00007. XXI. Savoia A, Accardo C, Vannini F, Di Pasquale B, Baldi A. Outcomes in thread lift for facial rejuvenation: a study performed with happy lift™ tevitalizing. Dermatology Ther (Heidelb) 2014;4(1):103-14. XXII. Sharma AN, Patel BC. Laser Fitzpatrick skin type recommendations (updated 2023 Mar 6). In: StatPearls (Internet). Treasure Island (FL): StatPearls Publishing; 2023 Jan. Disponible en: https://www.ncbi.nlm.nih.gov/ books/NBK557626/. XXIII. Pinsky MA, Thomas JA, Murphy DK, Walker PS; Juvéderm versus Zyplast Nasolabial Fold Study Group. Juvéderm injectable gel: a multicenter, double-blind, randomized study of safety and effectiveness. Aesthet Surg J. 2008 Jan-Feb;28(1):17-23. doi: 10.1016/j.asj.2007.09.005. Publisher An entity responsible for making the resource available <em>Editorial Lugones</em> Date A point or period of time associated with an event in the lifecycle of the resource 12/12/2023 Contributor An entity responsible for making contributions to the resource <em>Allanmar International Company S.R.L</em> Rights Information about rights held in and over the resource Legal records: Lugones® Editorial Seal. Director: Facundo Lugones. Editor: Lic. María Fernanda Cristoforetti. Owner: Editorial Biotecnológica S.R.L. Legal address: Av. Curapaligüe 202, 9° B (1406), City of Buenos Aires, Argentina. Authors of the Lugones article Editorial: Marcelo Robles. Reproduction rights: Lugones® Editorial Seal, Editorial Biotecnológica S.R.L. Total or partial reproduction of the articles is prohibited without the authorization of the author and the publisher. Work registered in the National Directorate of Copyright, Ministry of Justice and Human Rights of the Argentine Republic. Registration of Published Work-Web Page in File No.: RL-2021-41251755-APN-DNDA#MJ. Registration of Periodical Publications in File No.: RL-2023-71140630-APN-DNDA#MJ, City of Buenos Aires, Argentina. Format The file format, physical medium, or dimensions of the resource Website Language A language of the resource Spanish and english Type The nature or genre of the resource Scientific Identifier An unambiguous reference to the resource within a given context <a href="https://www.lugoneseditorial.com.ar/novedades/estudio-de-seguridad-y-eficacia-del-acido-hialuronico-reticulado-en-relleno-de-surcos-nasolabiales/">https://www.lugoneseditorial.com.ar/novedades/estudio-de-seguridad-y-eficacia-del-acido-hialuronico-reticulado-en-relleno-de-surcos-nasolabiales/</a> Coverage The spatial or temporal topic of the resource, the spatial applicability of the resource, or the jurisdiction under which the resource is relevant <em>Argentina, 2023</em> hyaluronic acid crosslinked nasolabial folds skin aging https://ciencia.lugoneseditorial.com.ar/files/original/30be7fd9a44d120a9881dd0404a36ae2.pdf c6df3afbf474e320d172268355cfb9bc Dublin Core The Dublin Core metadata element set is common to all Omeka records, including items, files, and collections. For more information see, http://dublincore.org/documents/dces/. Subject The topic of the resource Dermatología Title A name given to the resource Trabajos originales Publisher An entity responsible for making the resource available Sello Editorial Lugones Date A point or period of time associated with an event in the lifecycle of the resource 12/12/2023 Contributor An entity responsible for making contributions to the resource Futerman International Products Format The file format, physical medium, or dimensions of the resource Página web: https://www.lugoneseditorial.com.ar/novedades/estudio-prospectivo-evaluacion-de-la-eficacia-y-longevidad-del-acido-hialuronico-reticulado-en-relleno-de-surcos-nasolabiales/ Language A language of the resource Español Dublin Core The Dublin Core metadata element set is common to all Omeka records, including items, files, and collections. For more information see, http://dublincore.org/documents/dces/. Title A name given to the resource <strong>Prospective study</strong>: evaluation of the efficacy and longevity of cross-linked hyaluronic acid in filling nasolabial folds Subject The topic of the resource <em>Dermatology</em> Description An account of the resource <strong>Introduction</strong>: The choice of minimally invasive methods positions hyaluronic acid (HA) fillers as a leading facial rejuvenation technique. Injectable HA fillers have been widely used in the clinical treatment of facial wrinkles. However, additional information and clinical evidence on the longevity of HA filler after injection is limited. Objectives: demonstrate the efficacy, safety and longevity of cross-linked HA (AHR) 30 mg/ml (Estrianon Hyaluronic Implant 30® Allanmar International Company S.R.L., Argentina) for filling nasolabial folds (SNL). <strong>Design</strong>: multicenter, prospective, controlled clinical trial of 12 months duration. <strong>Materials and methods</strong>: 160 patients were included (132 women and 28 men, divided into cohorts of 30, 30 and 100 each) and an injectable gel of AHR 30 mg/ml was applied in the correction of SNL to evaluate safety. , effectiveness and longevity of the product. <strong>Results</strong>: a relevant correction of the depression in the sulci was observed that was maintained until the end of the study. The mean level of improvement was clinically significant in 94% of cases. The severity of NLS was reduced by approximately 2 points to the range of mild or barely noticeable. <strong>Conclusions</strong>: Estrianon Hyaluronic Implant 30® proved to be a safe, effective filler with considerable longevity. At 12 months, significant correction was still observed and the treatment was well tolerated by patients. Creator An entity primarily responsible for making the resource <em>Claudio Dachevsky, Héctor Llovera</em> Source A related resource from which the described resource is derived I. Sharma P, Sharma S. Comparative study of a new dermal filler Uma Jeunesse® and Juvéderm®. J Cosmet Dermatol 2011 Jun;10(2):118-25. doi: 10.1111/j.14732165.2011.00556.x. II. Chung C, Lee JH. A single-center, randomized, doubleblind clinical trial to compare the efficacy and safety of a new monophasic hyaluronic acid filler and biphasic filler in correcting nasolabial fold. Aesth Plast Surg 2021;45:2902-2908. doi: 10.1007/s00266-021-02252-0 III. Goldberg DJ. Breakthroughs in US dermal fillers for facial soft-tissue augmentation. J Cosmet Laser Ther 2009 Dec;11(4):240-7. doi: 10.3109/14764170903341731. IV. Gold M. The science and art of hyaluronic acid dermal filler use in esthetic applications. J Cosmet Dermatol 2009 Dec;8(4):301-7. doi: 10.1111/j.14732165.2009.00464.x. V. Beer K. Dermal fillers and combinations of fillers for facial rejuvenation. Dermatol Clin 2009 Oct;27(4):42732. doi: 10.1016/j.det.2009.08.011. VI. Grunebaum LD, Bogdan Allemann I, Dayan S, Mandy S, Baumann L. The risk of alar necrosis associated with dermal filler injection. Dermatol Surg 2009 Oct;35(Suppl 2):1635-40. doi: 10.1111/j.1524-4725.2009.01342.x. VII. Hirsch R, Stier M. Complications and their management in cosmetic dermatology. Dermatol Clin 2009 Oct;27(4):507-20. doi: 10.1016/j.det.2009.08.013. VIII. Qiao J, Jia QN, Jin HZ, Li F, He CX, Yang J, Zuo YG, Fu LQ. Long-term follow-up of longevity and diffusion pattern of hyaluronic acid in nasolabial fold correction through high-frequency ultrasound. Plast Reconstr Surg 2019 Aug;144(2):189e-196e. doi: 10.1097/ PRS.0000000000005848. IX. Young SR, Bolton PA, Downie J. Use of high-frequency ultrasound in the assessment of injectable dermal fillers. Skin Res Technol 2008 Aug;14(3):320-3. doi: 10.1111/j.1600-0846.2008.00297.x. X. Marinho A, Nunes C, Reis S. Hyaluronic acid: a key ingredient in the therapy of inflammation. Biomolecules 2021 Oct 15;11(10):1518. doi: 10.3390/biom11101518. XI. Day DJ, Littler CM, Swift RW, Gottlieb S. The Wrinkle Severity Rating Scale: a validation study. Am J Clin Dermatol 2004;5(1):49-52. doi: 10.2165/00128071200405010-00007. XII. Savoia A, Accardo C, Vannini F, Di Pasquale B, Baldi A. Outcomes in thread lift for facial rejuvenation: a study performed with happy lift™ tevitalizing. Dermatology Ther (Heidelb) 2014;4(1):103-14. doi: 10.1007/s13555014-0041-6. XIII. Sharma AN, Patel BC. Laser Fitzpatrick skin type recommendations (updated 2023 Mar 6). In: StatPearls (Internet). Treasure Island (FL): StatPearls Publishing; 2023 Jan. Disponible en: https://www.ncbi.nlm.nih.gov/ books/NBK557626/. XIV. Mark G. Rubin, treatment of nasolabial folds with fillers. Aesthetic Surgery Journal 2004;24(5):489-493. doi: 10.1016/j.asj.2004.06.004. XV. Shaw RB Jr, Katzel EB, Koltz PF, Yaremchuk MJ, Girotto JA, Kahn DM, Langstein HN. Aging of the facial skeleton: aesthetic implications and rejuvenation strategies. Plast Reconstr Surg 2011 Jan;127(1):374-383. doi: 10.1097/PRS.0b013e3181f95b2d. XVI. Brandt FS, Cazzaniga A. Hyaluronic acid fillers: Restylane and Perlane. Facial Plast Surg Clin North Am 2007 Feb;15(1):63-76. doi: 10.1016/j.fsc.2006.11.002. XVII. Allergan. Instrucciones de uso. Disponible en https:// www.rxabbvie.com/pdf/juvederm-ultra_dfu.pdf. XVIII. Allergan. Instrucciones de uso. Disponible en: https:// www.rxabbvie.com/pdf/juvederm-ultra-plus-xc_dfu.pdf. XIX. Galderma. Instrucciones de uso. Disponible en: https:// www.galderma.com/us/sites/default/files/2018-11/ Restylane_IFU.pdf. XX. Narins RS, Brandt F, Leyden J, Lorenc ZP, Rubin M, Smith S. A randomized, double-blind, multicenter comparison of the efficacy and tolerability of Restylane versus Zyplast for the correction of nasolabial folds. Dermatol Surg 2003 Jun;29(6):588-95. doi: 10.1046/j.15244725.2003.29150.x. XXI. Li D, Xie Y, Li Q, Sun J, Jiang P, Jia Y, Murphy DK, Li Q. Safety and effectiveness of Juvéderm Ultra Plus injectable gel in correcting severe nasolabial folds in Chinese subjects. Plast Reconstr Surg Glob Open 2017 Jan 16;5(1):e1133. doi: 10.1097/GOX.0000000000001133. XXII. Goodman GJ, Bekhor P, Rich M, Rosen RH, Halstead MB, Rogers JD. A comparison of the efficacy, safety, and longevity of two different hyaluronic acid dermal fillers in the treatment of severe nasolabial folds: a multicenter, prospective, randomized, controlled, single-blind, within-subject study. Clin Cosmet Investig Dermatol 2011;4:197-205. doi: 10.2147/CCID.S26055. XXIII. Baumann LS, Shamban AT, Lupo MP, Monheit GD, Thomas JA, Murphy DK, Walker PS; Juvéderm vs. Zyplast nasolabial fold study group. Comparison of smooth-gel hyaluronic acid dermal fillers with cross-linked bovine collagen: a multicenter, double-masked, randomized, within-subject study. Dermatol Surg 2007 Dec;33(Suppl 2):S128-35. doi: 10.1111/j.1524-4725.2007.33352.x. XXIV. Lupo MP, Smith SR, Thomas JA, Murphy DK, Beddingfield FC III. Effectiveness of Juvéderm Ultra Plus dermal filler in the treatment of severe nasolabial folds. Plast Reconstr Surg 2008 Jan;121(1):289-297. doi: 10.1097/01. prs.0000294968.76862.83. XXV. Pinsky MA, Thomas JA, Murphy DK, Walker PS; Juvéderm vs. Zyplast Nasolabial Fold Study Group. Juvéderm injectable gel: a multicenter, double-blind, randomized study of safety and effectiveness. Aesthet Surg J 2008 Jan-Feb;28(1):17-23. doi: 10.1016/j.asj.2007.09.005. XXVI. Solish N, Bertucci V, Percec I, Wagner T, Nogueira A, Mashburn J. Dynamics of hyaluronic acid fillers formulated to maintain natural facial expression. J Cosmet Dermatol 2019 Jun;18(3):738-746. doi: 10.1111/ jocd.12961. Publisher An entity responsible for making the resource available <em>Editorial Lugones</em> Date A point or period of time associated with an event in the lifecycle of the resource 12/12/2023 Contributor An entity responsible for making contributions to the resource <em>Allanmar International Company S.R.L</em> Rights Information about rights held in and over the resource <strong>Legal records</strong>: Lugones® Editorial Seal. <strong>Director</strong>: Facundo Lugones. <strong>Editor</strong>: Lic. María Fernanda Cristoforetti. <strong>Owner</strong>: Editorial Biotecnológica S.R.L. <strong>Legal address</strong>: Av. Curapaligüe 202, 9° B (1406), City of Buenos Aires, Argentina. Authors of the Lugones article Editorial: Marcelo Robles, Claudio Dachevsky, Héctor Llovera Reproduction rights: Lugones® Editorial Seal, Editorial Biotecnológica S.R.L. Total or partial reproduction of the articles is prohibited without the authorization of the author and the publisher. Work registered in the National Directorate of Copyright, Ministry of Justice and Human Rights of the Argentine Republic. Registration of Published Work-Web Page in File No.: RL-2021-41251755-APN-DNDA#MJ. Registration of Periodical Publications in File No.: RL-2023-71140630-APN-DNDA#MJ, City of Buenos Aires, Argentina. Format The file format, physical medium, or dimensions of the resource Website Language A language of the resource English and spanish Type The nature or genre of the resource Scientific Identifier An unambiguous reference to the resource within a given context <a href="https://www.lugoneseditorial.com.ar/novedades/estudio-prospectivo-evaluacion-de-la-eficacia-y-longevidad-del-acido-hialuronico-reticulado-en-relleno-de-surcos-nasolabiales/#">https://www.lugoneseditorial.com.ar/novedades/estudio-prospectivo-evaluacion-de-la-eficacia-y-longevidad-del-acido-hialuronico-reticulado-en-relleno-de-surcos-nasolabiales/#</a> Coverage The spatial or temporal topic of the resource, the spatial applicability of the resource, or the jurisdiction under which the resource is relevant <em>Argentina, 2023</em> Global Aesthetic Improvement hyaluronic acid nasolabial folds